Skip to main content
European Commission logo print header

Improvement of a therapeutic adjuvanted protein hiv vaccine by combination with dna immunization in prime-boost regimen (HIVPRIMEBOOSTTHERVAC)

Obiettivo

An optimal immunotherapeutic regimen will be established and its efficacy evaluated in HIV-infected individuals. The proposal comprises the improvement of an adjuvant protein HIV vaccine for therapeutic use that has proved efficacious in a stringent rhesus monkey SHIV challenge rode. The irnprovement will be achieved through combination of the adjuvant protein vaccine with particle-mediated immune delivery of DNA in prime-boost immunization regimen. This regimen will be investigated in mice and rhesus monkeys for superior immunogenicity and efficacy. One or several prime-boost immunization regimen will be evaluated in initial phase I clinical trials in exonerative volunteers. If the prime-boost combinations are immunogenic, the best combination will be tested for its efficacy in a therapeutic trial in HIV-Positive patients.

Invito a presentare proposte

Data not available

Meccanismo di finanziamento

CSC - Cost-sharing contracts

Coordinatore

GLAXOSMITHKLINE BIOLOGICALS SA
Contributo UE
Nessun dato
Indirizzo
Rue de l'Institut 89
--- RIXENSART
Belgio

Mostra sulla mappa

Costo totale
Nessun dato

Partecipanti (2)